Results 151 to 158 of about 5,159 (158)

Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)

Journal of the American College of Cardiology, 2014
Frederick J Raäl, Robert P Giugliano, Marc S Sabatine   +2 more
exaly  

Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia

Journal of the American College of Cardiology, 2019
Michael J Koren, Marc S Sabatine, Robert P Giugliano   +2 more
exaly  

Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance

Journal of the American College of Cardiology, 2014
Erik S G Stroes, David R Sullivan, Leslie Cho   +2 more
exaly  

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

Lancet, The, 2015
Frederick J Raäl, Narimon Honarpour, Dirk J Blom   +2 more
exaly  

Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab

Annals of Pharmacotherapy, 2015
C Michael White
exaly  

Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Pre‐specified analysis of the Chinese population from the BERSON clinical trial

Diabetes, Obesity and Metabolism, 2019
Zuyi Yuan, Juming Lu, Freddy G Eliaschewitz   +2 more
exaly  

Evaluation of Evolocumab (AMG 145), a Fully Human Anti‐PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment

Journal of Clinical Pharmacology, 2017
John P Gibbs, J Greg Slatter, Lisa Hamilton   +2 more
exaly  

Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Primary results of the BERSON clinical trial

Diabetes, Obesity and Metabolism, 2019
Alberto J Lorenzatti, Freddy G Eliaschewitz, Juming Lu   +2 more
exaly